Teriparatide vs abaloparatide
Teriparatide and abaloparatide are FDA-approved anabolic peptides for osteoporosis that act at the PTH1 receptor. This page compares their origins in PTH and PTHrP, structures, proposed signaling differences, pivotal trials, regulatory status and analytical concerns.
Teriparatide is the N-terminal 34-residue fragment of human parathyroid hormone (PTH), produced by recombinant DNA technology and approved by the FDA as Forteo. Abaloparatide is a synthetic analogue of the first 34 residues of parathyroid hormone-related protein (PTHrP), with several substitutions, approved as Tymlos.
Both bind the type 1 PTH receptor (PTH1R) and, under the conditions used in their approved products, stimulate bone formation more than bone resorption. They are the main examples of anabolic bone peptides and are often compared because they share a receptor but differ in sequence, receptor-conformation preference and trial evidence. See also calcitonin, an anti-resorptive peptide.
Side-by-side
| Attribute | Teriparatide | Abaloparatide |
|---|---|---|
| Origin | Human PTH(1-34) | Analogue of human PTHrP(1-34) |
| Production | Recombinant | Chemical synthesis |
| Modifications | None; native sequence with free C-terminus | Several substitutions including Aib; C-terminal amide |
| Receptor target | PTH1R | PTH1R |
| Proposed signaling difference | Binds both R0 and RG receptor conformations, giving more sustained signaling (proposed) | Prefers the RG conformation, giving more transient signaling (proposed) |
| Pivotal trial | Fracture Prevention Trial in postmenopausal women | ACTIVE, which included a placebo arm and an open-label teriparatide arm |
| FDA status | Approved (Forteo) | Approved (Tymlos) |
| WADA | Check the current WADA Prohibited List | Check the current WADA Prohibited List |
| Analytical pitfalls | Oxidation at Met8 and Met18; host-cell impurities; deamidation | Confirming non-standard residues and amide; synthesis deletion impurities |
| Storage | Lyophilized research material at -20 °C, protected from light; avoid freeze-thaw | Lyophilized research material at -20 °C, protected from light; avoid freeze-thaw |
PTH vs PTHrP origins
PTH is the main hormone controlling blood calcium, while PTHrP was first identified as the factor behind hypercalcemia in some cancers and later found to act locally in many tissues, including bone and cartilage. The two share a receptor and some sequence similarity at their N-termini, where receptor activation occurs, but diverge across most of the 34-residue region. Abaloparatide was engineered from the PTHrP sequence with substitutions intended to improve stability and tune receptor interactions.
Receptor conformation and bone effects
Pharmacology studies have proposed that PTH1R can adopt conformations described as R0 and RG. Teriparatide binds both, which has been linked to longer-lasting cyclic AMP signaling, whereas abaloparatide shows relative selectivity for RG and more transient signaling. This difference has been proposed to explain a more anabolic and less resorptive profile, and possibly less hypercalcemia, for abaloparatide. The model comes mainly from cell and animal work and is still debated; clinical differences should be read from trial data rather than inferred from receptor models.
Clinical evidence
Teriparatide's approval rested on the Fracture Prevention Trial in postmenopausal women with osteoporosis, which showed fewer new vertebral fractures than placebo. Abaloparatide's ACTIVE trial compared it with placebo and with open-label teriparatide and met its primary endpoint of reduced new vertebral fractures versus placebo. Long-term rat studies found osteosarcoma with both agents, which shaped their original labeling; current labeling should be checked for present warnings and limits. These are summaries of approved-drug trials, not general claims.
Frequently asked questions
What is the difference between teriparatide and abaloparatide?
Teriparatide is the native first 34 residues of human parathyroid hormone, made recombinantly. Abaloparatide is a synthetic, modified analogue of the first 34 residues of parathyroid hormone-related protein. Both activate the PTH1 receptor, but abaloparatide is reported to favor a receptor conformation linked to shorter signaling, which has been proposed to explain differences seen in studies.
Are teriparatide and abaloparatide FDA approved?
Yes. Teriparatide is approved as Forteo and abaloparatide as Tymlos, both for osteoporosis in patients at high risk of fracture, with details set out in their labeling. Biosimilar or follow-on teriparatide products also exist in some markets, so current listings should be checked. Research-grade material is not equivalent to approved products.
How is teriparatide checked analytically?
Identity is confirmed by mass spectrometry against the expected mass of PTH(1-34), with peptide mapping often used for full sequence confirmation. Teriparatide has methionines at positions 8 and 18, so oxidized variants are key impurities to monitor. Recombinant material should also be tested for host-cell proteins and endotoxin. See the guide on endotoxin testing.
Full entries
- Teriparatide
Teriparatide is the N-terminal 34-amino-acid fragment of human parathyroid hormone, PTH(1-34). It is an FDA-approved bone-forming (anabolic) agent, marketed as Forteo, used for osteoporosis in people at high risk of fracture.
- Abaloparatide
Abaloparatide is a synthetic 34-amino-acid analogue of parathyroid hormone-related protein, PTHrP(1-34). It is an FDA-approved anabolic agent for osteoporosis, marketed as Tymlos, that acts on the PTH type 1 receptor.
Cite this page